271 related articles for article (PubMed ID: 30988140)
1. Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.
Lee A; Prideaux B; Lee MH; Zimmerman M; Dolgov E; Perlin DS; Zhao Y
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30988140
[TBL] [Abstract][Full Text] [Related]
2. Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
Schmitt-Hoffmann AH; Kato K; Townsend R; Potchoiba MJ; Hope WW; Andes D; Spickermann J; Schneidkraut MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971866
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
4. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazonium sulfate for the treatment of fungal infection.
Walker RC; Zeuli JD; Temesgen Z
Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
7. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
10. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
12. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
Pfaller MA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazole for Treatment of Experimental Fungal Endophthalmitis Caused by Aspergillus fumigatus.
Guest JM; Singh PK; Revankar SG; Chandrasekar PH; Kumar A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201814
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
Kovanda LL; Maher R; Hope WW
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
18. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
Garcia-Vidal C
Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Seyedmousavi S; Verweij PE; Mouton JW
Expert Rev Anti Infect Ther; 2015 Jan; 13(1):9-27. PubMed ID: 25488140
[TBL] [Abstract][Full Text] [Related]
20. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]